Neuropeptide immunocorrection in patients with multiple sclerosis
Comparison in people · 2025
- What was studied
- 63 adults with MS, ages 18–59: 33 standard therapy plus Cortexin; 30 standard therapy alone
- Main finding
- After three courses, the authors report upper-limb motor-score gains of 1.4 versus 0.8 points and lower-limb gains of 1.8 versus 0.9, with reported p<0.05. The proportion described as having reduced work capacity fell from 71.7% to 31.1% with adjunct Cortexin, versus 75.5% to 53.1% in controls. These are reported functional signals, not evidence of disease modification.
p<0.05 as reported
Reported findings and study design
63 adults with MS aged 18–59: standard care plus Cortexin 33 versus standard care 30; results reported after three courses.
Population or model 63 adults with MS, ages 18–59: 33 standard therapy plus Cortexin; 30 standard therapy alone
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Upper-limb motor-score gain | 1.4 versus 0.8 points | p<0.05 as reported |
| Lower-limb motor-score gain | 1.8 versus 0.9 points | p<0.05 as reported |
| Reduced-work-capacity proportion, add-on arm | 71.7% → 31.1% | |
| Reduced-work-capacity proportion, comparison arm | 75.5% → 53.1% |
Existing full-article extraction; the motor scale and variance are not adequately specified, and percentages lack raw counts. No MRI, relapse or EDSS progression benefit is established.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- Small comparison with unclear allocation, baseline comparability, concomitant therapy and assessment timing; no placebo or blinding described.
- Motor scale, variance and statistical methods are insufficiently specified. Percentages lack underlying counts; immune-marker claims have no numerical table.
- No longitudinal MRI lesion, relapse-rate or EDSS progression outcomes are reported. Safety reporting is insufficient; this does not establish an MS treatment or replacement for disease-modifying therapy.
- A same-title 2021 Artykova–Rakhmatov report exists; cohort overlap remains unresolved and is not counted as independent replication.
Related publications may describe some of the same participants or experiments.
Source details
Open-access journal PDF; Zenodo repository
Methods, results, tables and references reviewed. Randomization, blinding and allocation procedures are not described; this is not classified as a randomized trial.
Full article read; motor table visually checked
Sources checked
Citation
M. A. Artykova, S. A. Beknazarov. Neuropeptide immunocorrection in patients with multiple sclerosis Scientific and Innovative Therapy. 2025;(2):3–9. Bukhara State Medical Institute; Zenodo deposit 5 June 2025
Study source ↗ · DOI 10.5281/zenodo.15635394 · Bibliography entry · Link to this summary